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Abstract
Plants produce and store many organic compounds like amino acids, proteins, carbo-
hydrates, fats, and alkaloids, which are usually treated as secondary metabolites. Many 
alkaloids are biologically active for humans. For thousand years, extracts from plants con-
taining alkaloids had medicinal use as drugs and they owe their powerful effects thanks 
to presence of alkaloids. Alkaloids have anti-inflammatory, antibacterial, analgesic, local 
anesthetic, hypnotic, psychotropic, antimitotic, and antitumor activity. Nowadays, alka-
loids from plants are still of great interest to organic chemists, pharmacologists, biolo-
gists, biochemists, and pharmacists. Plants of Liliaceae family contain colchicine as the 
main alkaloid, which has cytotoxic activity. Colchicine has limited pharmacological 
application because of its toxicity, but many derivatives have been synthesized and their 
cytotoxic activity and tubulin-binding properties have been tested. Many of the synthetic 
derivatives showed good cytotoxic activity.
Keywords: colchicine, colchinoids, plants containing colchicine alkaloids, cytotoxic 
compounds, cancer cell lines, cytotoxic activity
1. Introduction
One of the best known biologically active compounds from ancient times is colchicine 
(Figure 1), an alkaloid naturally occurring in Colchicum autumnale a plant of Liliaceae family 
and also in Gloriosa superba. In the past, extracts from these plants containing colchicine were 
useful in gout therapy and still are [1]. The anti-gout action of colchicine could be explained 
by its powerful spindle toxicity [2, 3]. Moreover, colchicine is a useful medicine in the treat-
ment of familial Mediterranean fever (FMF), liver cirrhosis, chronic myelocytic leukemia, 
Behçet disease, chondrocalcinosis and other microcrystalline arthritis also more recently in 
cardiovascular diseases, Sweet’s syndrome, and hepatic disorders (HCC hepatocellular car-
cinoma) [4–12].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
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In 2009, the FDA approved colchicine for the treatment of gout and familial Mediterranean 
fever (FMF) [1]. Recent investigations utilizing large cohorts of gout patients who have been 
taking colchicine for years have demonstrated novel applications within oncology, immu-
nology, cardiology, and dermatology [4, 13–16]. Some emerging dermatologic uses include 
the treatment of epidermolysis bullosa acquisita, leukocytoclastic vasculitis, and aphthous 
stomatitis. Colchicine has also anti-inflammatory and anticancer properties. Colchicine has 
been proven to have a fairly narrow range of effectiveness as a chemotherapy agent though it 
is also occasionally used in veterinary medicine to treat cancers in some animals. Nowadays, 
colchicine is very useful as an antimitotic agent in cancer research involving cell culture [17]. 
Colchicine has limited medical usage because of its high toxicity [18]. Because of this reason, 
many attempts have been made to design, synthesize new colchicine derivative and to screen 
them as cytotoxic agents to search more biologically active/effective compounds with lower 
toxicity.
2. Cytotoxic colchinoids in plants
Colchicine 1 and related alkaloids were isolated from many plants of Liliaceae family. The 
Colchicum species are most known plants in which colchicine exists in majority and other col-
chicine-like derivatives are in minority. Unripe seeds of Colchicum plants were found to con-
tain 40% less colchicine 1 than fully ripe one [19]. Colchicine occurs in all parts of Colchicum 
plants but especially in seeds and bulbs. One of the most known plants which contain col-
chicine 1 is meadow saffron (C. autumnale, Figure 2). The other plants of Colchicum sp. are: 
C. crocifolium, C. turicum, C. kesselvingii, C. luteum, C. byzantinum, C. crocifolium, C. szovitsii, 
C. soboliferum, and many more [20]. Beside 1 in these plants of Colchicum species also are 
present: 2-demethylcolchicine 2, 3-demethylcolchicine 3, demecolcine 4, 2-demethylcolchice-
ine 5, 3-demethylcolchiceine 6, N-methyl-demecolcine 7, 3-demethyl-N-methyl-demecolcine 
8, N-formyl-N-deacetylcolchicine 9 [19], N-deacetylcolchicine 10, N-deacetylcolchiceine 11, 
and colchiceine 12. Many of colchicine alkaloids exist in plants in glycoside form [21, 22]. 
Colchicine and its derivatives are also present in other plants like: Gloriosa superba, Merendera 
species (M. kurdica, M. sobolifera, M. vaddeana, M. robusta, and many more), Bulbocodium vernum, 
Androcymbium palaestinum, and Kreysigia multiflora [20, 23]. In Gloriosa superba plants were found 
Figure 1. Colchicine molecule (color version available on the online version).
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alkaloids: 1, 2, 5, 6, 2,3-O-didemethylcolchicine 13, 2,3-O-didemethyl-N-deacetylcolchicine 14, 
and 2,3-O-didemethyl-N-formyl-N-deacetylcolchicine 15 [22]. More recently, a new colchi-
cine glycoside, 3-O-demethylcolchicine-3-O-α-d-glucopyranoside 41 has been isolated from 
Gloriosa superba seeds [22]. Moreover, in plants extracts were also isolated photolysis products 
of colchicine like α-lumicolchicine, β-lumicolchicine, γ-lumicolchicine, and their 3-O-demethyl 
derivatives [24, 25].
3. Unusual chemical structure of colchinoids
Colchicine (1) is an alkaloid with unusual structure and has the whole family of structural 
relations. This alkaloid was isolated in 1820 by Pelletier and Caventou [26]. Although listed at 
this point, colchicines are biogenetically very close to the isoquinoline alkaloids. Colchicines 
posses exocyclic N-atoms [15]. Corrected structure of colchicine molecule with seven-mem-
bered C ring proposed Dewar in 1945 [27]. Colchicine possesses both one stereogenic center 
at C7 and chirality axis, since the two rings A and C are not positioned in coplanar fashion 
(atropisomerism). In naturally occurring (−)-aR,7S-colchicine, the two rings (A and C) are 
oriented in a clockwise manner [15].
4. Natural, semi-synthetic, and synthetic colchicines
Many naturally occurring colchicine alkaloids (some of them are listed in Figures 3 and 4) 
have been converted into semi-synthetic compounds and have been prepared as potential 
antitumor agents. Usually starting with colchicine 1 hundreds of semi-synthetic and synthetic 
colchicine derivatives have been synthesized [28–30].
Starting compound was 1,2-O-didemethylcolchicine 16 converted into 1,2,3-O-tridemethyl 
colchiceine 17 [28–30], 1,2,3-O-tridemethyl-N-deacetylcolchiceine 18 [28–30], 1,2,3-O-tride 
methyl-N-deacetyl-N-trifluoroacetylcolchiceine 19 [28–30], and 1,2,3-O-tridemethyl-N-deace 
Figure 2. Meadow saffron Colchicum autumnale: bulb, flowers, and leaves (color version available on the online version). 
(*author’s own photos).
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tyl-N-formyl(2,4,6-trihydroxyphenyl)colchiceine 20 [28–30]. 1,2-didemethyl-N-deacetylcol-
chicine 21 was converted into: 1,2-didemethyl-N-deacetyl-N-(propane-2,3-diol)colchicine 22 
[31] and 1,2-didemethyl-N-deacetyl-N-(propane-2,3-diacetyl)colchicine 23 [31]. Derivatives 
24 with halogene substituent and with alkyl, aryl, or hydrogen 25 at C-10 position have also 
been obtained [32]. 10-demetoxy-10-azido-colchicine 26 [33] and 10-demetoxy-10-amino-col-
chicine = colchiceinamide 27 [34]. 2-Demethyl-N-benzyldemecolcine = speciocolchine 28 [35] 
has been prepared from 2-demethyldemecolcine. 10-O-p-tosylsulfonylcolchiceine 29 can be 
converted into compound 24 [36]. One of the interesting derivatives modified at C-7 position 
by –sulfur-containing substituent is N-deacetyl-N-(2merkaptoacetyl)-colchicine 30 (DAMA-
colchicine) [37]. Glycopeptide dendrimer conjugates of colchicine modified at C-7 have been 
synthesized and tested as mitosis inhibitors [38]. N-substituted derivatives colchicine-lipids 
with different length of alkyl chain of olenyl and stearyl groups have been obtained and 
their interaction with lipid membrane has been studied [39]. Ring-C-modified colchicine 
analogs with different nitroso substituents in Diels-Alder reaction have been obtained [40]. 
3-Demethyl derivative of colchicine and 10-metylthiocolchicine have been obtained also by 
regioselective bioconversion of 1 and 31 by microorganisms Bacillus IND-B 375 and stain of 
Bacillus megaterium ACBT03 [41, 42].
Figure 3. Naturally occurring colchicine derivatives (color version available on the online version).
Figure 4. Natural, seminatural and synthetic colchicines (chosen examples).
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4.1. C-10 sulfur-containing derivatives
After many years of searching colchicine derivatives as good cytotoxic agents, it was estab-
lished that exchange of methoxyl substituent ─OCH
3









) and especially to methylthio (CH
3
S─) or alkylthio increases cytotoxic activ-
ity. Thiocolchicine 31 is a colchicine 1 derivative used in the therapy of some diseases [43] and 
extensively studied in the field of oncological research as antimitotic agent [44–46]. There were 
mentioned some of wide range of synthesized colchicine compounds with thio substituent at 
C-10 position during last 60 years. Derivatives with alkylthio substituent at C-10 position have 
been synthesized from colchicine 31–35 (Figure 5) [47]. N-deacetyl-10-methylthiocolchicine 36 
was converted into compounds: 37 [44], 38 and 39 [44]. 10-Methylthiocolchine was modified 
at C-3 position to compound 3-demethoxy-3-amino-10-methylthiocolchicine 40 and then to 
3-demethoxy-3-glycosylaminothiocolchicines 41–47 (Figure 5) [48]. From derivatives 48–52 
Figure 5. Seminatural and synthetic thiocolchicines (chosen examples).
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Figure 6. Thiocolchicines with modified ring A: 60 1,4-quinone and 61 quinomethane.
Figure 7. Thiocolchicines modified on ring B.
esters of 1-O-demethyl, 2-O-demethyl and 3-O-demethylthiocolchicine were also obtained 53–
57 (Figure 5) [49]. 10-methylthiocolchicine has been demethylated to 1-demethyl-10-methyl-
thiocolchicine 58, 2-demethyl-10-methylthiocolchicine 59, and 1,2-O-didemethylthiocolchicine 
52 then 58 and 59 have been oxidized to quinine (Figure 6) [50]. Complex ethers of 3-demethyl-
10-methylthiocolchicine 62–65 have been prepared as potential pharmaceuticals [51]. The C-7 
amide group of ring B with (R)-configuration [15] is also one of the crucial factors which decide 
of molecule’s anticancer activity. Eight synthetic derivatives of N-deacetylthiocolchicine have 
been obtained and tested against cancer cell lines and 3 of them showed good activity 66, 67, 
68 [52]. Thiocolchicine derivative 69 has been modified at C-2 carbon atom and then converted 
into salt 70 [53]. Among 37 thiocolchicine derivatives tested, compound 71 showed good activ-
ity as inhibitor of topoisomerases in vitro [54]. N-substituted thiocolchicine derivatives and 
their water-soluble phosphate salts 72–78 (and 5 others) have been obtained and their activity 
have been tested against cancer cell lines [55] (Figure 7).
Cytotoxicity50
From compound 79 acetamido ─NHCOCH
3
 substituent from C-7 has been removed and 
replaced by ═CH
2
 group [56]. Hybrids of vindoline, anhydrovinblastine, and vinorelbine 
with thiocolchicine 31 podophyllotoxin and baccatinIII have been tested in arresting cell cycle 
and cytotoxic activity [57]. Series of thiocolchicine-podophyllotoxin conjugates have been 
obtained and their tubulin activity has been tested [58].
Compounds 80, 81, 82, 83, 84, and 85 have been synthesized by four synthesis steps from 
colchicine 1 to thiocolchicine 31 then to 7-deacetylthiocolcicine 36 which has been con-
verted into 80 and then to 81, 82, 83, 84, 85 and eight others which possess six-membered 
ring B [59].
5. Bioactivity of colchicine and its derivatives
Colchicine 1 has been known and used from ancient times, despite its toxicity to cure acute 
gout attacks because of its anti-inflammatory properties. After administration of colchicine 1, 
it is mainly metabolized in liver via demethylation by cytochrome P450 system (isoform CYP 
3A4) to 2-demethylcolchicine 2 and 3-demethylcolchicine 3 [11]. Colchiceine 12 was described 
as a metabolite in rats produced by cytochrome P450 3A4 isoform [60], but it does not occur in 
humans in vivo [61]. Colchicine’s most common toxicity is gastrointestinal (nausea, vomiting, 
diarrhea, abdominal pain) which occurs during first 24 hours after overdose. Toxic effect of 
colchicine appears after oral administration of 7–60 mg of colchicine and is fatal, symptoms 
occur in about 4 h and death in about 4 days. Severe colchicine overdose may be treated with 
a colchicine-specific antigen-binding immunoglobulin [11].
Beside colchicine 1 has many naturally occurring derivatives many attempts have been made 
to discover more effective and less toxic analogs by modifying the substituents of its basic 
structure.
Colchicine blocks mitosis metaphase due to different anti-mitotic effects: disruption of mitotic 
spindle formation and second disruption of the sol-gel formation. Colchicine can also interact 
with lipid membranes. The interaction between colchicine and membrane results with sig-
nificant alternations of both the properties of the lipid membrane and alkaloid [39]. Tubulin 
is an α and β heterodimer initially identified as the cellular colchicine-tubulin protein [10, 
62]. Colchicine can interact with human serum albumin, which has been studied by spec-
troscopic method [63, 64]. Study of colchicine-tubulin complex showed that colchicine binds 
at the location where it prevents curved tubulin from adopting a straight structure, which 
inhibits assembly. Microtubules are cytoskeletal polymers of tubulin involved in many cel-
lular functions [65]. Their dynamic instability is controlled by many proteins and compounds 
such as colchicine.
Colchicine and its biologically active derivatives, especially thiocolchicine and its derivatives, 
have been extensively tested on cancer cell lines for in vitro cytotoxicity, in mice, evaluated 
for inhibition of tubulin polymerization [66], on axonal cytoskeleton of rat peroneus nerve 
[67]. Thiocolchicine has been studied as a potent compound to treat Peyronie’s disease [68]. 
Derivatives of thiocolchicine have been tested ex vivo to human T-lymphoblastoid (CEM) 
cells [69].
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6. Cytotoxic activity of colchicine and its derivatives
Cytotoxic activity of colchicine has been known for many decades. In 1968, it was known that 
colchicine can efficiently bind to tubulin. Its antitumor activity derives from its tubulin binding 
activity [39]. Nowadays, it is known that colchicine can act with α and β tubulin in microtu-
bules and disrupt the formation of microtubules. In past decades, many attempts have been 
made to design and synthesize new colchicine derivatives which could be less toxic and more 
effective compounds than colchicine as cytotoxic agents. On the basis of years of screening col-
chicine derivatives, their activity against human cancer cell lines structure: activity relationship 
has been established. It was found out that derivatives with alkylthio substituents at C-10 posi-
tion and modified at C-7 usually are more active and less toxic than colchicine. One of the most 
known active semi-synthetic colchicine derivatives is thiocolchicine (10-methylthiocolchicine) 
31. Some of the obtained derivatives seem to be effective and promising agents against selected 
human cancer cell lines and possibly in the future could be used as anticancer drugs. Cytotoxic 
activity of colchicine derivatives has been tested in in vitro experiments on mice (KLN205, 
A2C12, yB8, yD12, βD10, yA7, yA3, B3, βD5, A2B1, yD1) [70] or hamster (CHO-K1) [45] cancer 
cell lines and human cancer cell lines such as: MFC-7 human breast adenocarcinoma [40, 45, 
47, 54, 71, 72] and MDA-MB-231 [47, 72] human Caucasian breast adenocarcinoma, SK-Br-3 
human breast cancer cell line [46], DLD-1 [47] and LOVO [47] human colon adenocarcinoma, 
HCT-5 colon cancer, HCT-15 colon carcinoma [44, 45], A549 human lung adenocarcinoma [44, 
52–55, 57, 58, 70], DMS-114 small lung cell cancer [44], SKOV-3 ovarian cancer [46], OVCAR-3 
ovarian carcinoma [44], A2780 human ovarian carcinoma cell line [73], 1A9 human ovarian 
carcinoma [53], KB human epidermoid carcinoma [46, 53, 57], PC-3 prostate cancer [40], H460 
human large cell lung carcinoma [71], SF268 human astrocytoma [71], HTC-8 human ileocecal 
carcinoma cell [46, 57], DU-145 human prostate carcinoma [46], SKMEL-2 human skin malig-
nant melanoma [46, 54], SKMEL-5 human skin malignant melanoma [44], RXF-631 renal carci-
noma [44], SNB-19 CNS carcinoma [44], RPMI-7951 malignant melanoma [56], TE671 human 
medulloblastoma [56], HepG2 human hepatocyte carcinoma [70], CaCo-2 human colon car-
cinoma [70], and CAKI-1 kidney carcinoma [54]. As a positive control in cytotoxic tests were 
used: colchicine, doxorobucin or camptothecin and MTT tests [39, 57] or SRB tests MTS assay 
[70]. Values of IC
50
 for compounds 1, 4, 7, 8, 31, 32, 33, 34, and 35 are given in Table 1. Naturally 
occurring colchicine and other colchicine-like alkaloids were tested against human cancer cell 
lines and usually showed much better activity than parent compound.
Thiocolchicine 31 showed good activity against A2780 human ovarian carcinoma cell line with 
value of IC
50
 1.6 nM [73]. The water-soluble compound 69 (salt of succinic acid of N,N-dimethyl-
N-deacetylthiocolchicine) showed selective activity against HTC-8 0.022 μg/mL and SK-BR-3 
0.012 0.022 μg/mL cancer cells [46]. The second salt of succinic acid of N-deacetylthiocolchicine 
72 showed activity against five of tested cancer cell lines 0.001–0.005 μg/mL (HTC-8, SK-BR-3, 
A549, DU145, KB) [46].
Thiocolchicine derivative 83 modified at C-7 position showed good cytotoxic activity against 
A549, RPMI-7951, and TE671 cancer cell lines 0.001 nM/mL [56]. Derivatives 66, 67, and 68 
showed good cytotoxic activity against A549, SKOV-3, SKMEL-2, HCT-15, and MCF-7 can-
cer cell lines with IC
50
 values 5.2–29.8 nM [52]. 69 and 70 showed significant activity against 
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tumor cell lines: A549, 1A9, and KB with values of IC
50
 0.02–0.06 μg/mL [53]. Hybrids of vin-
doline, anhydrovinblastine, and vinorelbine with thiocolchicine have been tested in arresting 
cell cycle and against A549 cell lines [57].
Many of tested colchicine derivatives and thiocolchicine derivatives obtained by partial syn-
thesis were assayed measuring mitotic arrest in L1210 murine leukemia cell cultures [70], their 
binding to tubulin in vitro, their antitumor activity against the P388 lymphocytic leukemia 
screen in mice, and their inhibition of swelling produced in rat paws by injection with uric acid. 
To measure inhibition in binding different colchicine derivatives to tubulin, many tests have 
been used in vitro and in vivo: CD spectra [74], radiolabeled compounds, and cancer cell lines.
The effect on tubulin can be assessed in vitro by measuring inhibition of tubulin polymeriza-
tion [53, 66, 70] and binding of radiolabeled colchicine to tubulin [75]. Significant inhibition 
in binding to tubulin greater than colchicine 1 was observed with 3-demethylcolchicine (3), 
10-methylthiocolchicine 31, and 3-demethyl-10-methylthiocolchicine 48 [76]. Significant inhi-
bition of binding radiolabeled colchicine to purified tubulin was observed with thiocolchicine 
and 3-demethylthiocolchicine (Table 2).
Colchicine showed to be too much toxic to be used as a drug candidate for cancer diseases. 
Colchicine is much more less toxic than colchicine [77]. Through past decades many deriv-
atives were tested against cancer cell lines to checked their cytotoxic activity and activity 
in vitro to disrupt microtubule network and spindle formation. Binding of colchicine analogs 
to tubulin measured by competition for labeled colchicine is for 1 5 × 10−6, 31 4 × 10−6, and 41 
2–3 × 10−5 [76]. Inhibition of tubulin assembly by thiocolchicine derivatives 69 and 70 is IC
50
 
8.7 μM and IC
50
 3.8 μM, respectively [53]. The compounds 72, 76, and 77 showed potent inhi-
Cell line compound DLD-1 LoVo MCF-7 MDA MB-231 H460 SF268
1 43.0 [47] 118.8 [47] 41.3 [47] 25.3 [47] 32 [71] 25 [71]
4 — — 52 [71] — 44 [71] 39 [71]
7 — — 151 [71] — 165 [71] 354 [71]
8 — — 2440 [71] — 3200 [71] 981 [71]
31 4.2 [47] 13.6 [47] 55.5 [47] 81.2 [47] — —
32 51.2 [47] 19.5 [47] 56.1 [47] 148.3 [47] — —
33 71.8 [47] 56.1 [47] 764.4 [47] 704.2 [47] — —
34 177.3 [47] 149.6 [47] 564.2 [47] 1103.8 [47] — —
35 316.7 [47] 438.0 [47] 873.6 [47] 1773.3 [47] — —
Doxorubicin 510.6 [47] 520.2 [47] 1210.1 [47] 935.5 [47] — —
Camptothecin — — 0.309 [71] — 0.024 [71] 0.043 [71]
Table 1. The IC
50
 values (nM) of compounds tested against cancer cell lines: MCF-7 [47], MDA-MB-231 [47], DLD-1 [47], 
LoVo [47], H460 [71] and SF268 [71]. Data were obtained from triplicate experiments. Doxorubicin was used as positive 
control (MTT test) [47].
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bition of tubulin assembly IC
50
 = 0.8–1.1 μM, for comparison for 1 is 1,5 μM  [54]. Compound 
83 showed good inhibition of tubulin polymerization and inhibition of colchicine binding 
(%), IC
50
 3.4 μM and 60% and 79 IC
50
 2.4 μM and 91%; 82 IC
50
 6.6 μM and 78% [56]. Hybrid 
thiocolchicine-vindoline causes cell cycle arrest in the G2/M phase [57]. Inhibition of tubulin 
polymerization has been studied with thiocolchicine-podophyllotoxin conjugates, where 31 
was modified at C-7 substituent [63].
In vivo P388 mouse leukemia test data P388 for colchicine 1 is 0.5, 31 is 0.18, and 48 is 5 [mg/kg] [76].
7. Pharmacological use of colchinoids
7.1. Colchicine prodrugs
Some of colchicines have been tested as prodrugs. Zyn-linked™ colchicines which are con-
jugates of colchicine derivatives with proprietary lipophylic molecules (ZYN-160 4-formyl-
thiocolchicine, PKH139, PKH153, PKH147) via acid cleavable linkages (PKH155, PKH159, 
ZYN-217) produced prodrugs (PKH140, PKH154, PKH156, PKH158, ZYN-162) with enhanced 
antitumor activity (A2780 human ovarian carcinoma cell line) [73]. Conjugates have blocked 
cell in the G2/M phase of the cell cycle and were up to 100-fold less active in vitro than unlinked 
drug [73]. Ring B-modified colchicine derivative CT20126 showed immunosuppressive and 
cytotoxic activity [78]. N-acetylcolchinol phosphate is a prodrug (ZD6126) derived from colchi-
cine [79]. Thiocolchicine dimers IDN5404 and IDN5676 have been tested as prodrugs active as 
inhibitor of Topo-I and without loss of the spindle poison properties [80]. Colchitaxel is another 
active compound with cytotoxic activity which combines colchicine and paclitaxel [81].
7.2. Drugs with colchicine
Besides antitumor activity, colchicine has anti-inflammatory properties. Colchicine reduces the 
formation of uric acid crystals in the affected joint and thereby reduces the amount of acute 
inflammation and pain. It also decreases the levels of uric acid in the blood or the amount that 
is excreted in the urine. More recently colchicine has been proposed as a potential drug in treat-
ment for various conditions (except gout), what can open new way of its possible future applica-
tion. Nowadays, colchicine is the useful drug in illnesses: familial Mediterranean fever (FMF), 
Inhibitor added Inhibitor:radiolabeled colchicine (%)
1:1 10:1





Table 2. Inhibition [%] of binding radiolabeled colchicine to purified tubulin [76].
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liver cirrhosis, disk problems, Behçet syndrome, prevention of post-pericardial syndrome, pri-
mary biliary cirrhosis, hepatic cirrhosis, dermatitis herpetiformis, Paget’s disease of bone, pseu-
dogout, and idiopathic pulmonary fibrosis.
Colchicine can be used to treat familial Mediterranean fever in children 4 years of age and older.
Colchicine is available as a tablet, capsule, and a gel. In tablet form, it is available in a generic 
0.6 mg tablet and as Colcrys 0.6 mg tablet. It is available as a capsule in a generic form of 
0.6 mg and as Mitigare 0.6 mg capsule. There is a topical gel form of Colchicum autumnale, 
available as ColciGel. Colchicine is commonly administered orally, and use of the topical gel 
is rare. Due to toxicity of colchicine from 2009, the injectable form is not available. Dosing is 
dependent on age of patient and kind of illness.
Usually, colchicine is a major component of tablets or capsules in which in a single tablet or capsule 
its amount is in range of 0.5 or 0.6 mg, sometimes is used as an injection (disk problems). Usually 
a man/woman of 60 kg takes a dose of 0.5–4.8 mg/day [82, 83]. Since 2008, only oral use of colchi-
cine for patients is possible because of 50 cases of serious adverse events [84]. The known medi-
cines with colchicine are: Colchicum Dispert®, Colcrys, Mitigare, and Colchimax. Col-Benemid or 
Proben-C is a drug where next to colchicine probenecid is added as uricosuric agent.
7.3. Drugs with colchicine derivatives
One of the known colchicine derivatives that has been used for the treatment of Hodgkin’s lym-
phoma and chronic granulocytic leukemia is N-deacetyl-N-methylcolchicine, brand name is 
Colcemid [72]. Moreover, its efficacy against melanoma and prostatic cancer has been established.
Thiocolchicoside (=glucopyranosyl derivative of the semi-synthetic 3-O-demethylthiocolchicine 
41), is well-known as a muscle relaxing agent and as an anti-inflammatory drug substance 
[85]. This compound is registered in different countries under the trade names of Colcamyl, 
Coltramyl, Coltrax, Miorel, and Musco-Ril. Muscle spasm is one of the main factors responsible 
for chronic pain, and because this particular drug reduces muscle tone, it is used in therapy for 
the treatment of contractures and inflammatory conditions that affect the muscular system [48].
8. Docking studies
A new tool for searching new potent anticancer agents is docking studies. Some years ago 
it became possible to study new compounds of possible biological activity by new technical 
methods like molecular modeling and docking studies [37, 86–90].
9. Conclusion
The way to search new colchicine derivatives especially thiocolchicine derivatives seems to be 
worth trying because of its promising cytotoxicity. Many new derivatives have been obtained, 
have been tested for many different cancer cell lines, and many of them seem to be promising 
anticancer agents in the future.
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Scientists still keep designing and synthesizing more and more colchicine derivatives for 
searching almost ideal anticancer agent. New methods, such as molecular modeling and 
docking studies, seem to be useful tool in searching for new colchicine derivatives as effective 
cytotoxic agents.
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